On 28 June 2019, orphan designation EU/3/19/2177 was granted by the European Commission to Bayer AG, Germany, for regorafenib for the treatment of glioma.
Treatment of glioma
|Orphan designation status||
|EU designation number||
|Date of designation||
|December 2022||The product was withdrawn from the Union Register of orphan medicinal products on request of the Sponsor.|
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: